All News

Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/iYM3EOdSSM https://t.co/sruLP9adx3

Links:

Dr. John Cush RheumNow ( View Tweet)
child.guttate.psoriasis

Paradoxical Psoriasis in Kids Taking TNF Inhibitors

d Jack Cush, MD

A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor.

Read Article
Why Patients Don't Take Medicines This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost. https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/KNaFynAlXM https://t.co/okO0fLqM54

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

What is Colchicine Worth? (6.23.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

Read Article
Study of 28,360 #PsA pts shows blacks have signif more HTN (59 v 52%), DM (31 v 23%), obesity (47 v 30%), gout (12 v 8%); while whites have more cancer (20 v 16%), anxiety (28 v 23%) & OP (14 v 12). Rx (NSAIDs, TNFi, DMARDs) also unequal by race. https://t.co/Ok7vhTdS8g https://t.co/ozFIg9HNuy

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologic.choice.MD_.jpeg (keep)

Treatment Sequences Define Subphenotypes in RA Patients

d Jack Cush, MD

An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time. 

Read Article
cost.price_.drugs_.pills_.jpg

Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?

d Jack Cush, MD

Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?

Read Article
Cancer.risk_.jpg

Cancer Risk From RA, Not the Drugs

d Jack Cush, MD

While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy.

Read Article
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 62 RCTs, 16 LTEs of JAKi, placebo, TNFi, & MTX Rx pts shows that malignancy incidence rate =1.15-1.26/100 Pt-Yrs. Neoplasia risk w/ JAKi = PBO or MTX risk (IRR 0.71 & 0.77); but JAKi CA risk if compared to TNFi (IRR 1.50;1.16 to 1.94) https://t.co/uOgPFlJ2z1 https://t.co/Ynh6SMQdke

Links:

Dr. John Cush RheumNow ( View Tweet)
biosim.sign_.jpg

Biosimilars Match Biologic Originators in Rheumatoid Arthritis

d Jack Cush, MD

A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).

Read Article
RheumNow Eular 2023 Daily Recap Series - Day1 & 2 RheumNow faculty and reporters provide a daily recap of conference content coverage. https://t.co/GCDmZT5dyE https://t.co/tXV9qDmcEu

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

EULAR 2023 Notes from Milan (6.09.2023)

d Jack Cush, MD

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Read Article
question-mark-1872634_640.jpg

Combining a Tyk2 inhibitor with a JAKi in RA?

d Janet Pope, MD, MPH, FRCPC

At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.

Read Article
takayasu.jpg

New treatment for Takayasu’s arteritis?

d Janet Pope, MD, MPH, FRCPC

Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.

Read Article
Adherence to TNFi follows different trajectories Cluster 1: “moderate then high” 51% Cluster 2: “moderate then low” 20% Cluster 3: “low adherence, to discontinuation” 18% Cluster 4: “low then high adherence” 11% Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl
Aurelie Najm AurelieRheumo ( View Tweet)
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Dr. Antoni Chan synovialjoints ( View Tweet)
What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD
Janet Pope Janetbirdope ( View Tweet)
exhibitor.floor.ACR

EULAR 2023 – Day 3 Report

d Jack Cush, MD

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.